









市場行情
/
股票
/
nasdaq-bdtx
/

Black Diamond Therapeutics Inc

BDTX

2.600USD

+0.060+2.36%

收盤 12/22, 16:00（美東）報價延遲15分鐘

148.05M總市值

6.86本益比TTM



Black Diamond Therapeutics Inc

2.600

+0.060+2.36%

概覽公司財務分析

概覽

公司

財務

分析

關於 Black Diamond Therapeutics Inc 公司

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.

Black Diamond Therapeutics Inc簡介



公司代碼BDTX

公司名稱Black Diamond Therapeutics Inc

上市日期Jan 30, 2020

CEOVelleca (Mark A)

員工數量24

證券類型Ordinary Share

年結日Jan 30

公司地址245 First Street, 18Th Floor

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02142

電話16174175868

網址https://www.blackdiamondtherapeutics.com/

公司代碼BDTX

上市日期Jan 30, 2020

CEOVelleca (Mark A)

Black Diamond Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Ms. Erika Jones

Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer

85.15K

Dr. Ali Behbahani, M.D.

Independent Director

81.44K

+5.56%

Dr. Garry E. Menzel, Ph.D.

Independent Director

76.64K

-0.03%

Dr. Prakash Raman, Ph.D.

Independent Director

26.36K

+17.07%

Dr. Kapil Dhingra, M.D.

Independent Director

10.00K

Ms. Shannon Campbell

Independent Director

8.87K

Dr. Mark A. Velleca, M.D., Ph.D.

Chairman of the Board, President, Chief Executive Officer

Dr. Samarth Kulkarni, Ph.D.

Lead Independent Director

Dr. Sergey Yurasov, M.D., Ph.D.

Chief Medical Officer

-100.00%

Dr. Elizabeth Buck, Ph.D.

Co-Founder, Chief Scientific Officer

名稱

名稱/職務

職務

持股

持股變動

Ms. Erika Jones

Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer

85.15K

Dr. Ali Behbahani, M.D.

Independent Director

81.44K

+5.56%

Dr. Garry E. Menzel, Ph.D.

Independent Director

76.64K

-0.03%

Dr. Prakash Raman, Ph.D.

Independent Director

26.36K

+17.07%

Dr. Kapil Dhingra, M.D.

Independent Director

10.00K

Ms. Shannon Campbell

Independent Director

8.87K

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

T. Rowe Price Investment Management, Inc.

18.86%

Versant Ventures

10.89%

Vestal Point Capital, LP

9.74%

New Enterprise Associates (NEA)

7.81%

The Vanguard Group, Inc.

3.84%

其他

48.86%

持股股東

佔比

T. Rowe Price Investment Management, Inc.

18.86%

Versant Ventures

10.89%

Vestal Point Capital, LP

9.74%

New Enterprise Associates (NEA)

7.81%

The Vanguard Group, Inc.

3.84%

其他

48.86%

股東類型

持股股東

佔比

Investment Advisor

30.99%

Investment Advisor/Hedge Fund

20.59%

Venture Capital

19.08%

Hedge Fund

7.50%

Research Firm

1.42%

Individual Investor

0.99%

Pension Fund

0.02%

其他

19.41%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

251

45.27M

104.04%

+4.70K

2025Q3

261

45.26M

106.75%

+270.69K

2025Q2

263

45.72M

119.11%

-2.33M

2025Q1

244

48.05M

134.35%

-28.07M

2024Q4

236

55.25M

127.86%

-855.91K

2024Q3

237

56.09M

121.86%

+1.99M

2024Q2

230

54.06M

101.77%

+8.09M

2024Q1

233

46.69M

117.14%

-13.89M

2023Q4

222

46.16M

104.70%

+1.30M

2023Q3

240

44.37M

104.97%

-4.12M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

T. Rowe Price Investment Management, Inc.

10.51M

18.46%

+112.89K

+1.09%

Jun 30, 2025

Versant Ventures

6.21M

10.9%

-221.60K

-3.45%

Apr 11, 2025

Vestal Point Capital, LP

5.60M

9.84%

Jun 30, 2025

New Enterprise Associates (NEA)

4.45M

7.81%

Jun 30, 2025

The Vanguard Group, Inc.

2.10M

3.69%

-253.80K

-10.77%

Jun 30, 2025

Tang Capital Management, LLC

2.07M

3.64%

Jun 30, 2025

Marshall Wace LLP

737.88K

1.3%

+737.88K

Jun 30, 2025

Invus Public Equities Advisors, LLC

1.05M

1.84%

Jun 30, 2025

Millennium Management LLC

944.85K

1.66%

-159.06K

-14.41%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Fidelity Enhanced Small Cap ETF

0.05%

iShares Micro-Cap ETF

0.03%

Avantis US Small Cap Equity ETF

0.02%

Invesco RAFI US 1500 Small-Mid ETF

0.01%

DFA Dimensional US Small Cap Value ETF

iShares Russell 2000 Value ETF

iShares Health Innovation Active ETF

Vanguard US Momentum Factor ETF

ProShares Hedge Replication ETF

iShares Russell 2000 Growth ETF

Fidelity Enhanced Small Cap ETF

佔比0.05%

iShares Micro-Cap ETF

佔比0.03%

Avantis US Small Cap Equity ETF

佔比0.02%

Invesco RAFI US 1500 Small-Mid ETF

佔比0.01%

DFA Dimensional US Small Cap Value ETF

佔比0%

iShares Russell 2000 Value ETF

佔比0%

iShares Health Innovation Active ETF

佔比0%

Vanguard US Momentum Factor ETF

佔比0%

ProShares Hedge Replication ETF

佔比0%

iShares Russell 2000 Growth ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Black Diamond Therapeutics Inc的前五大股東是誰？



Black Diamond Therapeutics Inc的前五大股東如下：
T. Rowe Price Investment Management, Inc.
持有股份：10.51M
佔總股份比例：18.46%。
Versant Ventures
持有股份：6.21M
佔總股份比例：10.90%。
Vestal Point Capital, LP
持有股份：5.60M
佔總股份比例：9.84%。
New Enterprise Associates (NEA)
持有股份：4.45M
佔總股份比例：7.81%。
The Vanguard Group, Inc.
持有股份：2.10M
佔總股份比例：3.69%。